Navigation Links
183 New Medicines in Development for Diabetes

WASHINGTON, Dec. 11 /PRNewswire-USNewswire/ -- Nabe News in Brooklyn, New York recently reported that 183 new medicines are in development to fight diabetes. The report details a record number of drugs for this chronic disease currently in human clinical trials and awaiting approval by the U.S. Food and Drug Administration. The report was released by America's pharmaceutical research and biotechnology companies (PhRMA).

Diabetics do not produce or properly use insulin, a hormone needed to convert sugar, starches and other food into energy. This chronic disease affects 24.7 percent of Brooklyn's adults, or 449,900 people, according to the Centers for Disease Control and Prevention.

"This killer thrives in communities like ours, where poverty and fast food are prevalent," said Dr. Richard Becker, president and CEO of the Brooklyn Hospital Center.

Rep. Edolphus Towns, who suffers from diabetes, attended the event at the Brooklyn Hospital Center as well.

"Developing new drugs to treat diabetes here in New York City will help address one of the major diseases affecting our community," the lawmaker said. Of New York's five boroughs, Brooklyn has the second highest rate of diabetes.

According to PhRMA, one of the drugs in development significantly improves long-term blood sugar control and targets the dysfunction of pancreas cells, a dysfunction that causes high sugar level in type 2 diabetes, the most common form of the disease. Another medicine in development stimulates the release of insulin only when glucose levels become too high and by suppressing appetite in patients with type 2 diabetes.

"The medicines now in the research pipelines are contributing significantly to the incredible progress made by America's pharmaceutical research and biotechnology companies in developing new treatments for diabetes and related conditions," said Ed Belkin, PhRMA vice president for communications and public affairs.

To read the full story, go to the Nabe News web site.

SOURCE Pharmaceutical Research and Manufacturers of America

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. 92 Medicines and Vaccines now in Development for HIV/AIDS
2. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
3. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
4. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
5. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
6. Report on 750 New Medicines in Development for Cancer Released in Baton Rouge
7. European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
8. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
9. More Than 300 New Medicines Being Developed for Mental Illnesses
10. Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
11. New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
Post Your Comments:
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):